Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs – guidance (TA711)

NICE recommend guselkumab, alone or with methotrexate, for active psoriatic arthritis in adults whose disease has not responded to DMARDs or who cannot tolerate them with set restrictions.

SPS commentary:

Use should be restricted to patients with/where (all the following apply):

    Peripheral arthritis with 3 or more tender joints and 3 or more swollen joints,
    Moderate to severe psoriasis (a body surface area of at least 3% affected by plaque psoriasis and a PASI score greater than 10).
      2 conventional DMARDs and at least 1 biological DMARD have previously been trialled

 

National Institute for Health and Care Excellence